 SOUTH SAN FRANCISCO, Calif., Sept. 29, 2021 GLOBE NEWSWIRE -- Denali Therapeutics Inc. NASDAQ: DNLI, a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier BBB for neurodegenerative diseases, today announced upcoming presentations at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis NEALS Meeting being held virtually, October 6-7. 